;PMID: 3707613
;source_file_965.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..43] = [t:0..43]
;1)sentence:[e:49..160] = [t:49..160]
;2)section:[e:164..201] = [t:164..201]
;3)sentence:[e:205..378] = [t:205..378]
;4)sentence:[e:379..485] = [t:379..485]
;5)sentence:[e:486..651] = [t:486..651]
;6)sentence:[e:652..843] = [t:652..843]
;7)sentence:[e:844..1018] = [t:844..1018]
;8)sentence:[e:1019..1227] = [t:1019..1227]
;9)sentence:[e:1228..1389] = [t:1228..1389]
;10)sentence:[e:1390..1497] = [t:1390..1497]
;11)sentence:[e:1498..1716] = [t:1498..1716]
;12)sentence:[e:1717..1918] = [t:1717..1918]
;13)sentence:[e:1919..2037] = [t:1919..2037]
;14)sentence:[e:2038..2300] = [t:2038..2300]
;15)section:[e:2304..2348] = [t:2304..2348]

;section 0 Span:0..43
;Biochem Pharmacol. 1986 May 1;35(9):1481-9.
(SEC
  (FRAG (NNP:[0..7] Biochem) (NNP:[8..17] Pharmacol) (.:[17..18] .)
        (CD:[19..23] 1986) (NNP:[24..27] May) (CD:[28..33] 1;35-LRB-)
        (CD:[33..34] 9) (-RRB-:[34..35] -RRB-) (CD:[35..40] :1481)
        (::[40..41] -) (CD:[41..43] 9.)))

;sentence 1 Span:49..160
;Role of propiolaldehyde and other metabolites in the pargyline inhibition of
;rat  liver aldehyde dehydrogenase.
;[57..72]:substance:"propiolaldehyde"
;[83..94]:substance:"metabolites"
;[102..111]:substance:"pargyline"
;[137..159]:substance:"aldehyde dehydrogenase"
(SENT
  (NP-HLN
    (NP (NN:[49..53] Role))
    (PP (IN:[54..56] of)
      (NP
        (NP (NN:[57..72] propiolaldehyde))
        (CC:[73..76] and)
        (NP (JJ:[77..82] other) (NNS:[83..94] metabolites))))
    (PP (IN:[95..97] in)
      (NP
        (NP (DT:[98..101] the) (NN:[102..111] pargyline)
            (NN:[112..122] inhibition))
        (PP (IN:[123..125] of)
          (NP (NN:[126..129] rat) (NN:[131..136] liver)
             (NN:[137..145] aldehyde) (NN:[146..159] dehydrogenase)))))
    (.:[159..160] .)))

;section 2 Span:164..201
;DeMaster EG, Shirota FN, Nagasawa HT.
(SEC
  (FRAG (NNP:[164..172] DeMaster) (NNP:[173..175] EG) (,:[175..176] ,)
        (NNP:[177..184] Shirota) (NNP:[185..187] FN) (,:[187..188] ,)
        (NNP:[189..197] Nagasawa) (NNP:[198..201] HT.)))

;sentence 3 Span:205..378
;The metabolism of pargyline proceeds by way of three separate cytochrome
;P-450  catalyzed N-dealkylation reactions: N-depropargylation,
;N-demethylation and  N-debenzylation.
;[223..232]:substance:"pargyline"
;[267..283]:cyp450:"cytochrome P-450"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[205..208] The) (NN:[209..219] metabolism))
      (PP (IN:[220..222] of)
        (NP (NN:[223..232] pargyline))))
    (VP (VBZ:[233..241] proceeds)
      (PP (IN:[242..244] by)
        (NP
          (NP (NN:[245..248] way))
          (PP (IN:[249..251] of)
            (NP
              (NP (CD:[252..257] three) (JJ:[258..266] separate)
                (ADJP
                  (NML (NN:[267..277] cytochrome) (NN:[278..283] P-450))
                  (VBN:[285..294] catalyzed))
                (NN:[295..309] N-dealkylation) (NNS:[310..319] reactions))
              (::[319..320] :)
              (NP (NN:[321..339] N-depropargylation) (,:[339..340] ,)
                  (NN:[341..356] N-demethylation) (CC:[357..360] and)
                  (NN:[362..377] N-debenzylation)))))))
    (.:[377..378] .)))

;sentence 4 Span:379..485
;Propiolaldehyde, a product of N-depropargylation, is a potent  inhibitor of
;aldehyde dehydrogenase (AlDH).
;[379..394]:substance:"Propiolaldehyde"
;[398..405]:substance:"product"
;[442..451]:substance:"inhibitor"
;[455..477]:substance:"aldehyde dehydrogenase"
;[479..483]:substance:"AlDH"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[379..394] Propiolaldehyde))
      (,:[394..395] ,)
      (NP
        (NP (DT:[396..397] a) (NN:[398..405] product))
        (PP (IN:[406..408] of)
          (NP (NN:[409..427] N-depropargylation)))))
    (,:[427..428] ,)
    (VP (VBZ:[429..431] is)
      (NP-PRD
        (NP (DT:[432..433] a) (JJ:[434..440] potent) (NN:[442..451] inhibitor))
        (PP (IN:[452..454] of)
          (NP
            (NP (NN:[455..463] aldehyde) (NN:[464..477] dehydrogenase))
            (NP (-LRB-:[478..479] -LRB-) (NN:[479..483] AlDH)
                (-RRB-:[483..484] -RRB-))))))
    (.:[484..485] .)))

;sentence 5 Span:486..651
;The formation of pargyline-derived  propiolaldehyde by isolated rat liver
;microsomes in vitro was confirmed using  gas chromatographic/mass
;spectrometric techniques.
;[503..512]:substance:"pargyline"
;[522..537]:substance:"propiolaldehyde"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[486..489] The) (NN:[490..499] formation))
      (PP (IN:[500..502] of)
        (NP
          (ADJP (NN:[503..512] pargyline) (HYPH:[512..513] -)
                (VBN:[513..520] derived))
          (NN:[522..537] propiolaldehyde)))
      (PP (IN:[538..540] by)
        (NP (VBN:[541..549] isolated) (NN:[550..553] rat) (NN:[554..559] liver)
            (NNS:[560..570] microsomes)))
      (ADVP (FW:[571..573] in) (FW:[574..579] vitro)))
    (VP (VBD:[580..583] was)
      (VP (VBN:[584..593] confirmed)
        (NP-1 (-NONE-:[593..593] *))
        (S-MNR
          (NP-SBJ (-NONE-:[593..593] *))
          (VP (VBG:[594..599] using)
            (NP
              (NML
                (NML (NN:[601..604] gas) (JJ:[605..620] chromatographic))
                (SYM:[620..621] /)
                (NML (NN:[621..625] mass) (JJ:[626..639] spectrometric)))
              (NNS:[640..650] techniques))))))
    (.:[650..651] .)))

;sentence 6 Span:652..843
;The measured rates of  propiolaldehyde formation for uninduced and
;phenobarbital-induced microsomes in  vitro were 0.2 +/- 0.03 and 0.9 +/- 0.2
;mumole/30 min/g wet weight liver  respectively.
;[675..690]:substance:"propiolaldehyde"
;[719..732]:substance:"phenobarbital"
;[767..779]:quantitative-value:"0.2 +/- 0.03"
;[784..795]:quantitative-value:"0.9 +/- 0.2"
;[796..828]:quantitative-units:"mumole/30 min/g wet weight liver"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[652..655] The) (VBN:[656..664] measured) (NNS:[665..670] rates))
      (PP (IN:[671..673] of)
        (NP
          (NP (NN:[675..690] propiolaldehyde) (NN:[691..700] formation))
          (PP (IN:[701..704] for)
            (NP
              (NP (JJ:[705..714] uninduced)
                (NML-2 (-NONE-:[714..714] *P*)))
              (CC:[715..718] and)
              (NP
                (ADJP (NN:[719..732] phenobarbital) (HYPH:[732..733] -)
                      (VBN:[733..740] induced))
                (NML-2 (NNS:[741..751] microsomes)))))
          (ADVP (FW:[752..754] in) (FW:[756..761] vitro)))))
    (VP (VBD:[762..766] were)
      (NP-PRD
        (NP
          (NP
            (QP (CD:[767..770] 0.2) (SYM:[771..774] +/-) (CD:[775..779] 0.03))
            (NML-1 (-NONE-:[779..779] *P*)))
          (CC:[780..783] and)
          (NP
            (QP (CD:[784..787] 0.9) (SYM:[788..791] +/-) (CD:[792..795] 0.2))
            (NML-1 (NN:[796..802] mumole))))
        (PP (SYM:[802..803] /)
          (NP (CD:[803..805] 30) (NN:[806..809] min)))
        (PP (SYM:[809..810] /)
          (NP (NN:[810..811] g) (JJ:[812..815] wet) (NN:[816..822] weight)
              (NN:[823..828] liver))))
      (ADVP (RB:[830..842] respectively)))
    (.:[842..843] .)))

;sentence 7 Span:844..1018
;However, these rates may have been artificially low due to  competition
;between semicarbazide, the trapping agent, and microsomal proteins  for the
;generated propiolaldehyde.
;[924..937]:substance:"semicarbazide"
;[943..957]:substance:"trapping agent"
;[974..982]:substance:"proteins"
;[1002..1017]:substance:"propiolaldehyde"
(SENT
  (S
    (ADVP (RB:[844..851] However))
    (,:[851..852] ,)
    (NP-SBJ (DT:[853..858] these) (NNS:[859..864] rates))
    (VP (MD:[865..868] may)
      (VP (VB:[869..873] have)
        (VP (VBN:[874..878] been)
          (ADJP-PRD (RB:[879..891] artificially) (JJ:[892..895] low))
          (PP (JJ:[896..899] due)
            (PP (TO:[900..902] to)
              (NP
                (NP (NN:[904..915] competition))
                (PP (IN:[916..923] between)
                  (NP
                    (NP (NN:[924..937] semicarbazide))
                    (,:[937..938] ,)
                    (NP (DT:[939..942] the)
                       (VBG:[943..951] trapping) (NN:[952..957] agent))
                    (,:[957..958] ,) (CC:[959..962] and)
                    (NP (JJ:[963..973] microsomal) (NNS:[974..982] proteins))))
                (PP (IN:[984..987] for)
                  (NP (DT:[988..991] the) (VBN:[992..1001] generated)
                      (NN:[1002..1017] propiolaldehyde)))))))))
    (.:[1017..1018] .)))

;sentence 8 Span:1019..1227
;CO significantly inhibited the  microsome-catalyzed N-depropargylation
;reaction in vitro, whereas CoCl2  pretreatment of rats partially blocked the
;pargyline-induced rise in blood  acetaldehyde after ethanol.
;[1019..1021]:substance:"CO"
;[1117..1122]:substance:"CoCl2"
;[1167..1176]:substance:"pargyline"
;[1200..1212]:substance:"acetaldehyde"
;[1219..1226]:substance:"ethanol"
(SENT
  (S
    (NP-SBJ (NN:[1019..1021] CO))
    (ADVP (RB:[1022..1035] significantly))
    (VP (VBD:[1036..1045] inhibited)
      (NP (DT:[1046..1049] the)
        (ADJP (NN:[1051..1060] microsome) (HYPH:[1060..1061] -)
              (VBN:[1061..1070] catalyzed))
        (NN:[1071..1089] N-depropargylation) (NN:[1090..1098] reaction))
      (ADVP (FW:[1099..1101] in) (FW:[1102..1107] vitro))
      (,:[1107..1108] ,)
      (SBAR-ADV (IN:[1109..1116] whereas)
        (S
          (NP-SBJ
            (NP (NN:[1117..1122] CoCl2) (NN:[1124..1136] pretreatment))
            (PP (IN:[1137..1139] of)
              (NP (NNS:[1140..1144] rats))))
          (ADVP (RB:[1145..1154] partially))
          (VP (VBD:[1155..1162] blocked)
            (NP
              (NP (DT:[1163..1166] the)
                (ADJP (NN:[1167..1176] pargyline) (HYPH:[1176..1177] -)
                      (VBN:[1177..1184] induced))
                (NN:[1185..1189] rise))
              (PP (IN:[1190..1192] in)
                (NP (NN:[1193..1198] blood) (NN:[1200..1212] acetaldehyde)))
              (PP-TMP (IN:[1213..1218] after)
                (NP (NN:[1219..1226] ethanol))))))))
    (.:[1226..1227] .)))

;sentence 9 Span:1228..1389
;Inhibition of the low Km liver mitochondrial AlDH by  propiolaldehyde in
;vitro exhibited first-order kinetics, which is consistent  with irreversible
;inhibition.
;[1250..1252]:quantitative-name:"Km"
;[1273..1277]:substance:"AlDH"
;[1282..1297]:substance:"propiolaldehyde"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1228..1238] Inhibition))
      (PP (IN:[1239..1241] of)
        (NP (DT:[1242..1245] the)
          (NML (JJ:[1246..1249] low) (NN:[1250..1252] Km))
          (NN:[1253..1258] liver) (JJ:[1259..1272] mitochondrial)
           (NN:[1273..1277] AlDH)))
      (PP (IN:[1278..1280] by)
        (NP (NN:[1282..1297] propiolaldehyde)))
      (ADJP (FW:[1298..1300] in) (FW:[1301..1306] vitro)))
    (VP (VBD:[1307..1316] exhibited)
      (NP
        (NML (JJ:[1317..1322] first) (HYPH:[1322..1323] -)
             (NN:[1323..1328] order))
        (NNS:[1329..1337] kinetics))
      (,:[1337..1338] ,)
      (SBAR-ADV
        (WHNP-1 (WDT:[1339..1344] which))
        (S
          (NP-SBJ-1 (-NONE-:[1344..1344] *T*))
          (VP (VBZ:[1345..1347] is)
            (ADJP-PRD (JJ:[1348..1358] consistent)
              (PP (IN:[1360..1364] with)
                (NP (JJ:[1365..1377] irreversible) (NN:[1378..1388] inhibition))))))))
    (.:[1388..1389] .)))

;sentence 10 Span:1390..1497
;Acetaldehyde did not attenuate the inhibition of  AlDH by propiolaldehyde in
;vitro or by pargyline in vivo.
;[1390..1402]:substance:"Acetaldehyde"
;[1440..1444]:substance:"AlDH"
;[1448..1463]:substance:"propiolaldehyde"
;[1479..1488]:substance:"pargyline"
(SENT
  (S
    (NP-SBJ (NN:[1390..1402] Acetaldehyde))
    (VP (VBD:[1403..1406] did) (RB:[1407..1410] not)
      (VP (VB:[1411..1420] attenuate)
        (NP
          (NP (DT:[1421..1424] the) (NN:[1425..1435] inhibition))
          (PP (IN:[1436..1438] of)
            (NP (NN:[1440..1444] AlDH)))
          (PP
            (PP (IN:[1445..1447] by)
              (NP (NN:[1448..1463] propiolaldehyde)
                (ADJP (FW:[1464..1466] in) (FW:[1467..1472] vitro))))
            (CC:[1473..1475] or)
            (PP (IN:[1476..1478] by)
              (NP (NN:[1479..1488] pargyline)
                (ADJP (FW:[1489..1491] in) (FW:[1492..1496] vivo))))))))
    (.:[1496..1497] .)))

;sentence 11 Span:1498..1716
;Propargyl alcohol, a  substance which is metabolized to propiolaldehyde by
;alcohol dehydrogenase, also  inhibited AlDH in vivo and caused a
;quantitatively similar rise in blood  acetaldehyde after ethanol as
;pargyline.
;[1498..1515]:substance:"Propargyl alcohol"
;[1520..1529]:substance:"substance"
;[1554..1569]:substance:"propiolaldehyde"
;[1573..1594]:substance:"alcohol dehydrogenase"
;[1612..1616]:substance:"AlDH"
;[1676..1688]:substance:"acetaldehyde"
;[1695..1702]:substance:"ethanol"
;[1706..1715]:substance:"pargyline"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1498..1507] Propargyl) (NN:[1508..1515] alcohol))
      (,:[1515..1516] ,)
      (NP
        (NP (DT:[1517..1518] a) (NN:[1520..1529] substance))
        (SBAR
          (WHNP-1 (WDT:[1530..1535] which))
          (S
            (NP-SBJ-1 (-NONE-:[1535..1535] *T*))
            (VP (VBZ:[1536..1538] is)
              (VP (VBN:[1539..1550] metabolized)
                (NP-1 (-NONE-:[1550..1550] *))
                (PP (TO:[1551..1553] to)
                  (NP (NN:[1554..1569] propiolaldehyde)))
                (PP (IN:[1570..1572] by)
                  (NP-LGS (NN:[1573..1580] alcohol)
                          (NN:[1581..1594] dehydrogenase)))))))))
    (,:[1594..1595] ,)
    (VP
      (ADVP (RB:[1596..1600] also))
      (VP (VBD:[1602..1611] inhibited)
        (NP (NN:[1612..1616] AlDH))
        (ADVP (FW:[1617..1619] in) (FW:[1620..1624] vivo)))
      (CC:[1625..1628] and)
      (VP (VBD:[1629..1635] caused)
        (NP
          (NP (DT:[1636..1637] a) (RB:[1638..1652] quantitatively)
              (JJ:[1653..1660] similar) (NN:[1661..1665] rise))
          (PP (IN:[1666..1668] in)
            (NP (NN:[1669..1674] blood) (NN:[1676..1688] acetaldehyde)))
          (PP-TMP (IN:[1689..1694] after)
            (NP (NN:[1695..1702] ethanol)))
          (PP (IN:[1703..1705] as)
            (NP (NN:[1706..1715] pargyline))))))
    (.:[1715..1716] .)))

;sentence 12 Span:1717..1918
;Other putative metabolites of  pargyline, namely benzylamine and
;propargylamine, inhibited AlDH in vivo, albeit  to a lesser degree than
;pargyline, but neither of these amines inhibited AlDH  directly.
;[1732..1743]:substance:"metabolites"
;[1748..1757]:substance:"pargyline"
;[1766..1777]:substance:"benzylamine"
;[1782..1796]:substance:"propargylamine"
;[1808..1812]:substance:"AlDH"
;[1854..1863]:substance:"pargyline"
;[1886..1892]:substance:"amines"
;[1903..1907]:substance:"AlDH"
(SENT
  (S
    (S
      (NP-SBJ
        (NP
          (NP (JJ:[1717..1722] Other) (JJ:[1723..1731] putative)
              (NNS:[1732..1743] metabolites))
          (PP (IN:[1744..1746] of)
            (NP (NN:[1748..1757] pargyline))))
        (,:[1757..1758] ,)
        (NP
          (ADVP (RB:[1759..1765] namely))
          (NN:[1766..1777] benzylamine) (CC:[1778..1781] and)
           (NN:[1782..1796] propargylamine)))
      (,:[1796..1797] ,)
      (VP (VBD:[1798..1807] inhibited)
        (NP (NN:[1808..1812] AlDH))
        (ADVP (FW:[1813..1815] in) (FW:[1816..1820] vivo))
        (,:[1820..1821] ,)
        (PP
          (ADVP (IN:[1822..1828] albeit))
          (TO:[1830..1832] to)
          (NP
            (NP (DT:[1833..1834] a) (JJR:[1835..1841] lesser)
                (NN:[1842..1848] degree))
            (PP (IN:[1849..1853] than)
              (NP (NN:[1854..1863] pargyline)))))))
    (,:[1863..1864] ,) (CC:[1865..1868] but)
    (S
      (NP-SBJ
        (NP (DT:[1869..1876] neither))
        (PP (IN:[1877..1879] of)
          (NP (DT:[1880..1885] these) (NNS:[1886..1892] amines))))
      (VP (VBD:[1893..1902] inhibited)
        (NP (NN:[1903..1907] AlDH))
        (ADVP (RB:[1909..1917] directly))))
    (.:[1917..1918] .)))

;sentence 13 Span:1919..2037
;Monoamine oxidase was implicated in the conversion of benzylamine to  an
;active inhibitory species, possibly an imine.
;[1919..1936]:substance:"Monoamine oxidase"
;[1973..1984]:substance:"benzylamine"
;[1999..2017]:substance:"inhibitory species"
;[2031..2036]:substance:"imine"
(SENT
  (S
    (NP-SBJ-1 (NN:[1919..1928] Monoamine) (NN:[1929..1936] oxidase))
    (VP (VBD:[1937..1940] was)
      (VP (VBN:[1941..1951] implicated)
        (NP-1 (-NONE-:[1951..1951] *))
        (PP (IN:[1952..1954] in)
          (NP
            (NP (DT:[1955..1958] the) (NN:[1959..1969] conversion))
            (PP (IN:[1970..1972] of)
              (NP (NN:[1973..1984] benzylamine)))
            (PP (TO:[1985..1987] to)
              (NP
                (NP (DT:[1989..1991] an) (JJ:[1992..1998] active)
                   (JJ:[1999..2009] inhibitory) (NN:[2010..2017] species))
                (,:[2017..2018] ,)
                (NP
                  (ADVP (RB:[2019..2027] possibly))
                  (DT:[2028..2030] an) (NN:[2031..2036] imine))))))))
    (.:[2036..2037] .)))

;sentence 14 Span:2038..2300
;From these studies, we conclude  that propiolaldehyde was the primary
;metabolite responsible for the pargyline  inhibition of AlDH in vivo;
;however, certain amine metabolites may have  contributed to a lesser degree
;by conversion to yet unknown inhibitory forms.
;[2076..2091]:substance:"propiolaldehyde"
;[2108..2118]:substance:"metabolite"
;[2139..2148]:substance:"pargyline"
;[2164..2168]:substance:"AlDH"
;[2195..2212]:substance:"amine metabolites"
(SENT
  (S
    (PP (IN:[2038..2042] From)
      (NP (DT:[2043..2048] these) (NNS:[2049..2056] studies)))
    (,:[2056..2057] ,)
    (NP-SBJ (PRP:[2058..2060] we))
    (VP (VBP:[2061..2069] conclude)
      (SBAR (IN:[2071..2075] that)
        (S
          (NP-SBJ (NN:[2076..2091] propiolaldehyde))
          (VP (VBD:[2092..2095] was)
            (NP-PRD
              (NP (DT:[2096..2099] the) (JJ:[2100..2107] primary)
                  (NN:[2108..2118] metabolite))
              (ADJP (JJ:[2119..2130] responsible)
                (PP (IN:[2131..2134] for)
                  (NP
                    (NP (DT:[2135..2138] the) (NN:[2139..2148] pargyline)
                        (NN:[2150..2160] inhibition))
                    (PP (IN:[2161..2163] of)
                      (NP (NN:[2164..2168] AlDH)))
                    (ADVP (FW:[2169..2171] in) (FW:[2172..2176] vivo))))))
            (::[2176..2177] ;)
            (S-ADV
              (ADVP (RB:[2178..2185] however))
              (,:[2185..2186] ,)
              (NP-SBJ (JJ:[2187..2194] certain)
                 (NN:[2195..2200] amine) (NNS:[2201..2212] metabolites))
              (VP (MD:[2213..2216] may)
                (VP (VB:[2217..2221] have)
                  (VP (VBN:[2223..2234] contributed)
                    (PP (TO:[2235..2237] to)
                      (NP (DT:[2238..2239] a) (JJR:[2240..2246] lesser)
                          (NN:[2247..2253] degree)))
                    (PP (IN:[2254..2256] by)
                      (NP
                        (NP (NN:[2257..2267] conversion))
                        (PP (TO:[2268..2270] to)
                          (NP
                            (ADJP (RB:[2271..2274] yet)
                                  (JJ:[2275..2282] unknown))
                            (JJ:[2283..2293] inhibitory)
                             (NNS:[2294..2299] forms)))))))))))))
    (.:[2299..2300] .)))

;section 15 Span:2304..2348
;PMID: 3707613 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2304..2308] PMID) (::[2308..2309] :) (CD:[2310..2317] 3707613)
        (NN:[2318..2319] -LSB-) (NNP:[2319..2325] PubMed) (::[2326..2327] -)
        (NN:[2328..2335] indexed) (IN:[2336..2339] for)
        (NNP:[2340..2348] MEDLINE-RSB-)))
